An official website of the United States government Here’s how you know

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

In this section: Medical Countermeasures Initiative (MCMi)

About MCMi

MCMi is an FDA-wide initiative to coordinate medical countermeasure development, preparedness and response

FDA plays a critical role in protecting the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. FDA ensures that medical countermeasures (MCMs)—including drugs, vaccines and diagnostic tests—to counter these threats are safe, effective, and secure. More: About MCMi and our history

Sub-Topic Paragraphs

MCMi news and events

Medical countermeasure-related news, events, and related links

Examples of MCMs include drugs, vaccines, and devices, such as diagnostic tests and personal protective equipment.

What are medical countermeasures?

MCMs are FDA-regulated products that may be used in a public health emergency

Graphic representing history of the FDA Medical Countermeasures Initiative (MCMi)

MCMi history

More about MCMi, including history and contact information

MCMi newsletters

Subscribe to MCMi email updates and view previous newsletters

Image representing collaborative partnerships

MCMi collaborations

FDA works with government agencies, non-government organizations, universities, and research centers to support public health preparedness and response efforts

Various images representing activities of the Office of Counterterrorism and Emerging Threats, including law and policy, regulatory science, professional development, and medical countermeasure development and availability

Office of Counterterrorism and Emerging Threats (OCET)

OCET coordinates the MCMi, and is part of the FDA Office of the Chief Scientist. Learn more in FDA Organization.

MCMi Program Update report cover - FY 2022

Publications and reports

View the latest MCM-related reports from FDA, including annual program updates

Gavel and stethoscope, representing medical countermeasure-related counterterrorism legislation

MCM legal, regulatory & policy framework

Helping ensure that U.S. laws, regulations, and policies support preparedness and response for potential CBRN and emerging infectious disease threats.

FDA scientist dividing plasma from individuals recently infected with dengue or West Nile viruses into smaller volume samples for distribution. These samples were part of a reference panel FDA created for qualified Zika test manufacturers, to determine if their tests can differentiate flaviviridae antibodies—that is, if the test can accurately show if a person was infected with Zika, dengue or West Nile, as antibodies for these viruses are very similar.

MCM regulatory science

Developing the tools, standards, and approaches to assess MCM safety, efficacy, quality and performance, and helping translate new technology into innovative, safe, and effective MCMs.

Paragraph Header

Contact Us

Contact Point

Michael Mair, MPH
Assistant Commissioner for Counterterrorism Policy, and Director, OCET

AskMCMi@fda.hhs.gov

www.fda.gov/medicalcountermeasures

Twitter: @FDA_MCMi

Hours Available

Office of Counterterrorism and Emerging Threats

For Latest Updates Follow

Contact Point Twitter

@FDA_MCMi

Top

U.S. Food and Drug Administration

About MCMi

MCMi is an FDA-wide initiative to coordinate medical countermeasure development, preparedness and response